https://pharminent.com/strategic-news-watch/strategic-news-watch-october-9-2026/ 2026-10-09T15:33:44Z Pharminent en Strategic News Watch • October 9, 2026 2026-10-09T15:33:44Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-october-8-2026/ 2026-10-09T15:32:53Z Pharminent en Rare Disease & Gene Therapy Digest • October 8, 2026 2026-10-09T15:32:53Z Blog https://pharminent.com/viatris-to-acquire-pacira-in-1-7b-pain-drug-deal/ 2026-10-09T11:45:48Z Pharminent en Viatris to acquire Pacira in $1.7B pain drug deal 2026-10-09T11:45:48Z Blog https://pharminent.com/neuromarket-pulse/neuromarket-pulse-weekly-neuroscience-competitive-intelligence-october-7-2026/ 2026-10-08T16:13:14Z Pharminent en NeuroMarket Pulse • Weekly Neuroscience Competitive Intelligence • October 7, 2026 2026-10-08T16:13:14Z Blog https://pharminent.com/manufacturing-intelligence/manufacturing-intelligence-weekly-digest-october-7-2026/ 2026-10-08T16:13:09Z Pharminent en Manufacturing Intelligence • Weekly Digest • October 7, 2026 2026-10-08T16:13:09Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-october-8-2026/ 2026-10-08T16:12:37Z Pharminent en Strategic News Watch • October 8, 2026 2026-10-08T16:12:37Z Blog https://pharminent.com/fda-approves-pfizers-tukysa-combination-for-metastatic-breast-cancer/ 2026-10-08T11:45:43Z Pharminent en FDA approves Pfizer's Tukysa combination for metastatic breast cancer 2026-10-08T11:45:43Z Blog